Vesalio Announces Initial Use of its Uniquely Designed and FDA-approved NeVa VS Device
VESALIO announces the successful initial use of its NeVa VS device in the United States for the treatment of post-aneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm.